You are here:

darunavir 300mg tablets (Prezista)


Following a full submission

darunavir (Prezista®) is accepted for use within NHS Scotland, co-administered with ritonavir and in combination with other antiretroviral medicinal products, for the treatment of human immunodeficiency virus (HIV-1) infection in highly pre-treated adult patients who have failed on more than one regimen containing a protease inhibitor (PI).

At 24 and 48 weeks, darunavir, in combination with low dose ritonavir, showed a significant improvement in the reduction of viral load compared with other protease inhibitor plus ritonavir regimens.

Drug Details

Drug Name: darunavir 300mg tablets (Prezista)
SMC Drug ID: 378/07
Manufacturer: Tibotec (Janssen-Cilag Ltd)
Indication: Human immunodeficiency virus (HIV-1) infection
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Full submission
Status: Accepted
Date Advice Published: 11 June 2007